Company intelligence / Profile preview

Elthera

Schlieren, Zurich, Switzerlandelthera.com ↗

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Elthera is a Swiss biopharmaceutical company specializing in precision oncology drug development. They develop proprietary, first-in-class anti-L1CAM monoclonal antibodies for aggressive cancers, employing a personalized medicine approach with integrated companion diagnostics. The company has demonstrated preclinical proof-of-concept for its novel oncology therapy in tumor-bearing animal models.

Therapeutic areas: Oncology
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

LegoChem Biosciences

Beyond the preview

Go deeper on Elthera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elthera.